

CITATION REPORT

List of articles citing

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15

DOI: 10.1200/jco.1990.8.9.1483

Journal of Clinical Oncology, 1990, 8, 1483-96.

Source: <https://exaly.com/paper-pdf/21219745/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
554	Die adjuvante systemische Therapie beim Mammakarzinom heute. 1991 , 23, 49-56		
553	Adjuvant systemic therapy for early breast cancer. 1991 , 7, 283-90		2
552	Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. 1991 , 325, 1342-8		165
551	Long-term effects of adjuvant chemotherapy in breast cancer. 1992 , 31, 243-50		16
550	Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. 1992 , 3, 439-43		8
549	Does the breast cancer dollar make sense?. 1992 , 28, 486-91		21
548	The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. <i>British Journal of Cancer</i> , 1992 , 66, 1171-6	8.7	53
547	Integration of conservative surgery, radiotherapy, and chemotherapy for patients with early-stage breast cancer. 1992 , 2, 107-115		17
546	Contributions to the understanding and management of breast cancer. Steiner Award Lecture 1992. 1993 , 55, 179-80		
545	HIV testing and blood recipients. 1993 , 342, 1549-50		
544	HIV in the developing world. 1993 , 342, 1550		
543	Doxorubicin adjuvant combinations for breast cancer. 1993 , 342, 1550-1		3
542	IBCSG's reply. 1993 , 342, 1551		2
541	Quantum leaps in treatment of high-risk breast cancer? Prove it!. 1993 , 29A, 1488-93		5
540	Anthracyclines in the adjuvant treatment of breast cancer. 1993 , 45 Suppl 2, 4-9		3
539	Present status of anthracyclines in the adjuvant treatment of breast cancer. 1993 , 45 Suppl 2, 10-9; discussion 18-9		19
538	Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group. 1993 , 45 Suppl 2, 38-45		13

537	Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG). 1993 , 45 Suppl 2, 46-50; discussion 49-50	6
536	A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. 1992 , 29A, 37-43	13
535	Anthracyclines in the treatment of early breast cancer. 1993 , 45 Suppl 2, 1-3	1
534	Avm (adriamycin, vinblastine, methotrexate) neoadjuvant chemotherapy in advanced or inflammatory carcinoma of the breast. 1993 , 3, 869-72	
533	Trends in the Adjuvant Treatment of Breast Cancer. 1993 , 6, 44-46	
532	Radiotherapy-chemotherapy integration in breast-conservation therapy. 1993 , 27, 89-102	2
531	Late cardiac effects of adjuvant therapy: too soon to tell?. 1994 , 5, 196-8	7
530	Adjuvant therapy for breast cancer. 1994 , 331, 741; author reply 744-5	1
529	Computer model challenges breast cancer treatment strategy. 1994 , 12, 559-67	16
528	Present and future projects of the International Breast Cancer Study Group. 1994 , 74, 1139-49	11
527	Adjuvant systemic therapy for early breast cancer. 1994 , 74, 401-9	14
526	Radiation therapy in the management of distant breast cancer metastases. 1994 , 4, 283-291	2
525	A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. 1994 , 30A, 606-10	16
524	Systemic therapy in breast cancer: efficacy and cost utility. 1994 , 5, 198-212	16
523	Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. 1994 , 5, 209-16	64
522	Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer. 1994 , 51 Suppl 1, 33-9	2
521	Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. 1995 , 45, 199-226	46
520	Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence. 1995 , 76, 2497-503	90

519	Diagnosis and management of spinal metastases from breast cancer. 1995 , 23, 121-34		15
518	Today's Adjuvant Therapy in Breast Cancer: Who Should Receive What?. 1995 , 2, 107327489500200		
517	Meeting highlights: international consensus panel on the treatment of primary breast cancer. 1995 , 87, 1441-5		151
516	Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. 1995 , 31A, 1754-9		42
515	The use of anthracyclines in the adjuvant treatment of breast cancer. 1995 , 21, 199-214		3
514	Axillary dissection: current practice and technique. 1995 , 32, 257-323		55
513	Breast conservation therapy for invasive carcinoma of the breast. 1995 , 32, 191-248		8
512	Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. 1995 , 332, 901-6		816
511	The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. 1995 , 21, 146-50		6
510	The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. 1996 , 334, 1356-61		356
509	Postmenopausal breast cancer: is the short-term pain worth the long-term gain?. 1996 , 347, 1057-8		3
508	Metastases of unknown primary site. 1996 , 80, 153-71		37
507	Abstracts. 1996 , 14, 1-73		
506	A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. <i>Drug Safety</i> , 1996 , 15, 406-29	5.1	25
505	Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1136-45	2.2	89
504	Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1573-80	2.2	26
503	Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. <i>Breast Cancer Research and Treatment</i> , 1996 , 41, 161-70	4.4	18
502	Pregnancy and breast cancer. 1996 , 12, 370-5		29

501	The changing approach to the treatment of early breast cancer. 1996 , 334, 1397-9		1
500	Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. <i>British Journal of Cancer</i> , 1997 , 75, 301-5	8.7	106
499	Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1858-69	2.2	279
498	Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1897-905	2.2	50
497	Guidelines for systemic therapy of early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997 , 43, 259-76	4.4	10
496	The place of chemotherapy in the treatment of early breast cancer. <i>British Journal of Cancer</i> , 1998 , 78 Suppl 4, 16-20	8.7	14
495	Issues in the chemotherapy of breast cancer. 1998 , 53, 97-108		
494	[Radiation and concomitant chemotherapy after surgery for breast cancer: Arcosein study]. 1998 , 2, 469-74		5
493	[Respective roles of radiotherapy and chemotherapy in adjuvant treatment of cancer of the breast: theoretical importance and feasibility of chemoradiotherapy]. 1998 , 2, 723-31		
492	erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. 1998 , 90, 1361-70		549
491	Current Guidelines for the Diagnosis and Treatment of Breast Cancer. 1998 , 3, 239-250		8
490	New clinical trends in the adjuvant therapy of early stage breast cancer. 1998 , 37, 411-9		1
489	First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2392-400	2.2	135
488	Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. <i>Journal of Clinical Oncology</i> , 1999 , 17, 93-100	2.2	95
487	Measuring health-related quality of life. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2293	2.2	3
486	The HercepTest assay: another perspective. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2293-4	2.2	19
485	Doxorubicin Cardiotoxicity: Growing Importance. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2293c-2293c	2.2	12
484	AC Regimen. 1999 , 34, 921-923		

483	Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. 1999 , 43, 220-6	12
482	Adjuvant therapy of breast cancer: Update. 1999 , 10, S129-S138	2
481	Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. 1999 , 91, 1829-46	573
480	Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. 1999 , 45, 877-84	31
479	Treatment of early-stage breast cancer. 1999 , 23, 149-228	1
478	Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. 1999 , 37, 283-91	23
477	Guideline Document. 1999 , 11, S87-S133	1
476	Adjuvant systemic management of early stage carcinoma of the breast. 1999 , 8, 93-101	1
475	Locoregional failure rates in patients with involved axillary nodes after mastectomy and systemic therapy. 1999 , 9, 223-9	16
474	Role of postmastectomy radiotherapy: A medical oncology perspective. 1999 , 9, 241-6	6
473	Postmastectomy radiotherapy: future directions. 1999 , 9, 300-4	8
472	Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. 1999 , 15, 389-416	52
471	Oral alkylating agents for breast cancer therapy. 1999 , 58 Suppl 3, 1-9	12
470	Adjuvant systemic therapy for primary breast cancer. 1999 , 79, 1075-90	12
469	Chemotherapy: The patient's choice. 1999 , 3, 102-104	1
468	Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?. 1999 , 35, 1625-7	12
467	Adjuvant therapy for resectable breast cancer. 1999 , 13, 391-413, vi	6
466	Loco-regional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation. 1999 , 50, 267-75	32

465	Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Regimen. 1999 , 34, 1268-1277		
464	Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1689-700	2.2	378
463	Breast cancer during pregnancy: cases and review of treatment and prognosis. 2000 , 55, 102-9		8
462	Systemic therapy. 2000 , 12, 532-40		
461	Radiotherapy for postmastectomy local-regional recurrent breast cancer. 2000 , 23, 494-8		8
460	The predictive value of body protein for chemotherapy-induced toxicity. 2000 , 88, 796-803		81
459	Developments in chemotherapy of breast cancer. 2000 , 88, 3073-3079		70
458	Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. 2000 , 89, 2521-6		30
457	Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. <i>Breast</i> , 2000 , 9, 134-8	3.6	
456	Adverse events associated with chemotherapy for common cancers. 2000 , 20, 96S-103S		6
455	Early operable breast cancer. 2000 , 1, 210-20		5
454	Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. 2000 , 2, 587-93		27
453	Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). 2000 , 7, 361-9		28
452	Therapeutische Möglichkeiten beim Mammakarzinom. 2000 , 6, S2-S4		
451	[Retrospective analysis of dose intensity of epirubicin in breast cancer]. 2000 , 40, 145-52		0
450	Docetaxel in the Adjuvant Setting. 2000 , 23, 10-12		
449	Anthrazykline in der adjuvanten Therapie des Mammakarzinoms. 2000 , 23, 7-11		
448	What threshold for adjuvant therapy in older breast cancer patients?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1709-17	2.2	179

447	2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3558-85	2.2	575
446	Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2817-27	2.2	329
445	Do We Have Good Surrogate Endpoints for Survival in Breast Cancer Studies?. 2000 , 86, 4-10		
444	Breast cancer update. <i>Oncologist</i> , 2000 , 5, 285-92	5.7	1
443	HER-2/neu als prädiktiver Faktor beim Mammakarzinom. 2000 , 60, 609-619		1
442	Wirksamkeit korreliert mit dem Menopausenstatus - Adjuvante Chemotherapie des Mammakarzinoms -. 2000 , 32, 65-71		
441	High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. <i>Oncologist</i> , 2000 , 5, 1-13	5.7	33
440	HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. 2000 , 92, 1991-8		222
439	Long-term chemotherapy-related cardiovascular morbidity. 2000 , 26, 429-47		75
438	Indicaciones de quimioterapia en cáncer de mama. 2000 , 97, 105-114		1
437	Multidisciplinary care for patients with breast cancer. 2000 , 80, 505-33		19
436	Overview of epirubicin-based adjuvant therapy in breast cancer. 2000 , 1 Suppl 1, S41-5		3
435	Selection criteria for epirubicin-based adjuvant chemotherapy in node-negative breast cancer. 2000 , 1 Suppl 1, S57-61		2
434	Epirubicin in breast cancer: present and future. 2000 , 1 Suppl 1, S62-7		6
433	Side effects of adjuvant treatment of breast cancer. 2001 , 344, 1997-2008		488
432	Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. 2001 , 2, 138-43; discussion 144		16
431	Present state and future prospects: a review of cooperative groups' adjuvant and neoadjuvant trials in breast cancer. 2001 , 2 Suppl 1, S20-30		5
430	Optimum anthracycline-based chemotherapy for early breast cancer. 2001 , 2, 469-74		10

429	Standard medical treatment for early breast cancer. 2001 , 37 Suppl 7, S45-58		3
428	National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. 2001 , 93, 979-89		578
427	Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. <i>Journal of Clinical Oncology</i> , 2001 , 19, 612-20	2.2	28
426	Anthracycline adjuvant chemotherapy: how much is enough?. <i>Journal of Clinical Oncology</i> , 2001 , 19, 599-601		16
425	Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial. 2001 , 60, 221-7		2
424	Dose-intensity, dose-escalation, and dose-density in the adjuvant chemotherapy of primary, operable breast cancer. 2001 , 14, 81-9		1
423	Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. <i>Journal of Clinical Oncology</i> , 2001 , 19, 602-11	2.2	243
422	Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. 2001 , 24, 328-35		28
421	Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition. 2001 , 24, 425-8		32
420	Progress in systemic chemotherapy of primary breast cancer: an overview. 2001 , 72-9		34
419	Taxanes in the adjuvant treatment of breast cancer: why not yet?. 2001 , 88-95		26
418	ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. 2001 , 12, 1047-8		23
417	Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. <i>Journal of Clinical Oncology</i> , 2001 , 19, 931-42	2.2	217
416	Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3103-10	2.2	140
415	Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1539-69	2.2	659
414	Overview of the US consensus conference on adjuvant therapy for breast cancer. <i>Breast</i> , 2001 , 10, 139-146		34
413	Optimal adjuvant cytotoxic therapy for breast cancer. <i>Breast</i> , 2001 , 10, 106-113	3.6	4
412	A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer. 2001 , 12, 1011-3		5

411	What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?. 2001 , 3, 523-8		
410	Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns. 2001 , 3, 529-35		1
409	Adjuvant therapy for breast cancer--results from the USA consensus conference. 2001 , 8, 298-304		53
408	The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer. 2001 , 8, 321-8		5
407	Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. 2001 , 92, 1354-67		72
406	Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. <i>Breast Cancer Research and Treatment</i> , 2001 , 66, 225-37	4.4	40
405	Doxorubicin and cyclophosphamide adjuvant chemotherapy is no more effective than cyclophosphamide, methotrexate, and 5-fluorouracil for premenopausal axillary lymph node positive breast cancer. 2001 , 2, 83-86		
404	Anthracyclines in breast cancer: therapy and issues of toxicity. <i>Breast</i> , 2001 , 10, 8-15	3.6	10
403	Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women. 2001 , 36-43		61
402	Adjuvant therapy for very young women with breast cancer: need for tailored treatments. 2001 , 44-51		135
401	Adjuvant treatment in node-negative, postmenopausal breast cancer. 2001 , 19, 706-22		
400	National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. 2001 , 2001, 5-15		115
399	Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. 2001 , 135-42		205
398	Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy. 2002 , 184, 169-89		0
397	A pitfall in the survival benefit of adjuvant chemotherapy for node- and hormone receptor-positive patients with breast cancer: the paradoxical role of Bcl-2 oncoprotein (review). 2001 , 19, 1075-80		1
396	Biostatistical Methods. 2001 ,		3
395	Medical management of breast cancer: today and tomorrow. 2002 , 17, 137-49		9
394	Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens. 2002 , 29, 881-6		3

393	Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. 2002 , 17, 218-24		18
392	The expanding role of epirubicin in the treatment of breast cancer. 2002 , 9, 16-27		14
391	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. 2002 , 62, 185-9		44
390	The value of adjuvant treatment in young women with breast cancer. 2002 , 62, 1-11		10
389	Premenopausal breast cancer: chemotherapy and endocrine therapy. 2002 , 62, 2025-38		5
388	Optimizing Anthracycline Therapy for Node Positive Breast Cancer. 2002 , 1, 257-268		6
387	Adjuvant therapy in breast cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2002 , 29, 201-8, ix	3-3	4
386	Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study. 2002 , 38, 2279-88		13
385	Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4611-4	2.2	28
384	Breast Cancer and Pregnancy. 2002 , 88, 187-192		6
383	Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. 2002 , 95, 228-35		8
382	Evidence for the use of chemotherapy in breast cancer. 2002 , 7, 254-64		10
381	Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy. 2002 , 52, 980-8		54
380	Pulsed electrostatic fields (ETG) to reduce hair loss in women undergoing chemotherapy for breast carcinoma: a pilot study. 2002 , 11, 244-8		24
379	Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. <i>British Journal of Cancer</i> , 2002 , 86, 1705-14	8.7	56
378	Adjuvant chemotherapy for breast cancer. 2002 , 387, 109-116		5
377	Delay in adjuvant radiation treatment and outcomes of breast cancer--a review. <i>Breast Cancer Research and Treatment</i> , 2002 , 74, 77-94	4.4	37
376	Using cost-effectiveness analysis to define a breast cancer benefits package for the uninsured. <i>Breast Cancer Research and Treatment</i> , 2002 , 74, 143-53	4.4	12

375	Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?. <i>Breast Cancer Research and Treatment</i> , 2002 , 75 Suppl 1, S37-44; discussion S57-9	4.4	5
374	Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents--more or less. 2002 , 14, 263-6		4
373	Adjuvant chemotherapy in early breast cancer: optimal and suboptimal anthracycline-containing regimens. <i>Breast Cancer Research and Treatment</i> , 2003 , 80, 313-20	4.4	5
372	Progress in systemic adjuvant therapy of early-stage breast cancer. 2003 , 8, 239-47		5
371	Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. <i>Breast</i> , 2003 , 12, 569-82	3.6	30
370	Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. 2003 , 70, 553-61		163
369	Long-term review of a breast conservation series and patterns of care over 18 years. 2003 , 73, 577-83		15
368	Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3357-65	2.2	573
367	Evidence-based indications for postmastectomy irradiation. 2003 , 83, 995-1013		43
366	Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 2003 , 10, 369-75		4
365	Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer. 2003 , 4, 264-72		4
364	Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 976-83	2.2	1050
363	Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer. 2003 , 29, 449-52		1
362	Advances in the Use of Taxanes in the Adjuvant Therapy of Breast Cancer. 2003 , 4, 187-192		20
361	Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1431-9	2.2	1245
360	Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. <i>Oncologist</i> , 2003 , 8 Suppl 2, 10-6	5.7	19
359	The sequencing of radiation therapy and chemotherapy after mastectomy in premenopausal women with breast cancer. 2003 , 33, 563-9		4
358	Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4524-31	2.2	364

357	Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. <i>Journal of Clinical Oncology</i> , 2003 , 21, 46-53	2.2	250
356	Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 298-305	2.2	83
355	Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3462-8	2.2	61
354	Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. 2003 , 14, 693-8		39
353	Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet!. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2444; author reply 2445-7	2.2	
352	. 2003 , 26, 229-231		4
351	Arm edema after lumpectomy and breast irradiation. 2003 , 26, 229-31		19
350	[Adjuvant chemotherapy in primary breast cancer]. 2003 , 26 Suppl 7, 17-20		2
349	Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. 2003 , 26, 115-9		1
348	Delay of radiation therapy and outcomes of breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1342-3; author reply 1343-4	2.2	3
347	Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group. 2004 , 21, 3-13		2
346	Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. 2004 , 170, 983-94		77
345	Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4247-54	2.2	302
344	[Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results]. 2004 , 44, 102-12		2
343	Benefits and costs of interventions to improve breast cancer outcomes in African American women. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2554-66	2.2	50
342	Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. <i>British Journal of Cancer</i> , 2004 , 90, 1306-11	8.7	252
341	Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. <i>Breast Cancer Research and Treatment</i> , 2004 , 86, 153-64	4.4	55
340	A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2004 , 88, 187-96	4.4	51

339	Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2004 , 88, 209-15	4.4	81
338	Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. 2004 , 5, 125-30		15
337	[Radiation and concomitant chemotherapy after surgery for breast cancer]. 2004 , 8, 39-47		9
336	Managing early breast cancer: prognostic features guide choice of therapy. 2004 , 116, 23-6, 32-4		1
335	Pregnancy-associated breast cancer. 2005 , 11, 83-95		37
334	National Surgical Adjuvant Breast and Bowel Project. 2005 ,		
333	1998-1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I-II breast cancer. 2005 , 62, 183-92		52
332	Cardiotoxicity of cancer therapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7685-96	2.2	263
331	Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status. 2005 , 20, 487-96		58
330	Australian patterns of practice survey in the adjuvant systemic treatment of early breast cancer. 2005 , 1, 25-33		
329	Adjuvant chemotherapy for early breast cancer: Is cyclophosphamide, methotrexate and 5-fluorouracil still the standard?. 2005 , 1, 13-24		2
328	Adjuvante Chemotherapie beim Mammakarzinom. 2005 , 38, 416-424		
327	Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?. 2005 , 53, 81-9		17
326	Taxanes in adjuvant breast cancer setting: which standard in Europe?. 2005 , 55, 167-75		20
325	«Cancers du sein». 2005 , 7, 342-379		12
324	Adjuvant chemotherapy for primary breast cancer. 2005 , 7, 18-22		2
323	Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?. <i>Breast Cancer Research and Treatment</i> , 2005 , 94, 95-103	4.4	12
322	Impact of Concurrent Radiotherapy on Chemotherapy Total Dose and Dose Intensity in Patients with Early Breast Cancer. 2005 , 91, 126-130		1

321	Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. 2005 , 16, 1449-57		83
320	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3686-96	2.2	501
319	Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8313-21	2.2	100
318	Undertreatment of obese women receiving breast cancer chemotherapy. 2005 , 165, 1267-73		202
317	Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2686-93	2.2	139
316	Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. 2005 , 12 Suppl 1, S125-33		20
315	Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1379-89	2.2	135
314	Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. 2005 , 60, 1137-44		24
313	Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5166-70	2.2	166
312	Role of chemotherapy in breast cancer. 2005 , 5, 1095-110		7
311	Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. 2005 , 2, 276-7		
310	Chemotherapy: what progress in the last 5 years?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1760-75	2.2	87
309	Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6908-18	2.2	79
308	Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. <i>Journal of Clinical Oncology</i> , 2005 , 23, 30-40	2.2	83
307	Cáncer de mama (y II). Estrategias terapéuticas. 2005 , 9, 1692-1703		
306	Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. 2005 , 6, 886-98		107
305	Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. 2005 , 19, 263-81, vi		34
304	A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer. 2005 , 23, 215-21		6

303	Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin. <i>Oncologist</i> , 2005 , 10, 780-91	5.7	51
302	Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?. 2005 , 31, 69-78		1
301	The choice of systemic adjuvant therapy in receptor-positive early breast cancer. 2005 , 41, 357-64		10
300	Radiotherapy for In Situ, Stage I, and Stage II Breast Cancer. 2005 , 499-536		
299	Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. 2005 , 11, 21-30		22
298	Adjuvant docetaxel for node-positive breast cancer. 2005 , 352, 2302-13		773
297	Cancer du sein. 2006 ,		
296	Breast Cancer and Molecular Medicine. 2006 ,		2
295	Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5381-7	2.2	407
294	Adjuvant therapy for patients who have node-positive breast cancer. 2006 , 40, 77-98		3
293	Adjuvant Chemotherapy in Primary Breast Cancer. 2006 , 1, 238-241		1
292	Surviving the perfect storm: an RVU-based model to evaluate the continuing impact of MMA on the practice of oncology. 2006 , 4, 3-15		1
291	Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. 2006 , 64, 496-504		47
290	A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. 2006 , 64, 1072-80		61
289	Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 255-62	4.4	112
288	Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. <i>Breast</i> , 2006 , 15, 269-72	3.6	2
287	Adjuvant chemotherapy for breast cancer--30 years later. 2006 , 355, 1920-2		36
286	HER2 and responsiveness of breast cancer to adjuvant chemotherapy. 2006 , 354, 2103-11		447

285	La chimiothérapie adjuvante. Quels sont les nouveaux standards ?. 2006 , 417-426		
284	Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4888-94	2.2	260
283	Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4100-6	2.2	308
282	Breast Cancer in Women of African Descent. 2006 ,		3
281	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2028-37	2.2	349
280	Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. 2006 , 17, 1497-503		60
279	Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. <i>Oncologist</i> , 2006 , 11, 111-25	5-7	45
278	Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. 2006 , 2, 527-37		12
277	Adjuvant chemotherapy for high-risk operable breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1642-4		7
276	Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. 2007 , 99, 506-15		28
275	Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. 2007 , 18, 1632-40		78
274	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. 2007 , 18, 1177-84		8
273	Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer. 2007 , 35, 753-61		4
272	Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. 2007 , 13, 4092-7		16
271	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. 2007 , 19, 56-62		76
270	Adjuvant biologic therapy for breast cancer. 2007 , 13, 156-61		2
269	Breast cancer chemotherapy. 2007 , 13, 141-7		13
268	Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. 2007 , 43, 877-84		49

267	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. 2007 , 33, 474-83		14
266	Adjuvant chemotherapy for early-stage breast cancer. 2007 , 21, 207-22		1
265	Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. 2007 , 18, 314-316		
264	Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. <i>British Journal of Cancer</i> , 2007 , 97, 1642-7	8.7	8
263	Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. 2007 , 13, 258-65		89
262	Quality indicators for the care of breast cancer in vulnerable elders. 2007 , 55 Suppl 2, S258-69		4
261	HER2/neu in systemic therapy for women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 209-29	4.4	74
260	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 27-44	4.4	257
259	Advances in Breast Cancer Management, Second Edition. <i>Cancer Treatment and Research</i> , 2008 ,	3.5	1
258	Breast Cancer 2nd edition. 2008 ,		1
257	Chemotherapy for Breast Cancer. 2008 , 345-385		1
256	Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 2008 , 34, 223-30		10
255	Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. 2008 , 34, 378-90		247
254	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. 2008 , 12, 1123-37		16
253	HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. 2008 , 100, 14-20		303
252	Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. 2008 , 21, 46-56		
251	HER-2 and topoisomerase II as predictors of response to chemotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 736-44	2.2	143
250	Paclitaxel and docetaxel in the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2603-16	4	83

249	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4092-9	2.2	82
248	Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. 2008 , 100, 805-14		174
247	Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. 2008 , 100, 121-33		123
246	Breast. 190-213		
245	Radiotherapy in Italy after Conservative Treatment of Early Breast Cancer. A Survey by the Italian Society of Radiation Oncology (AIRO). 2008 , 94, 333-341		8
244	The Incidence of Chemotherapy-induced Amenorrhea and Recovery in Young (. 2009 , 12, 20		5
243	A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. <i>British Journal of Cancer</i> , 2009 , 100, 305-10	8.7	32
242	Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients. 2009 , 39, 478-83		31
241	Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2474-81	2.2	152
240	Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer. 2009 , 21, 558-65		0
239	Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard. 2009 , 5, 481-4		2
238	Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer. 2009 , 5, 135-47		3
237	Anthracyclines and early breast cancer: the end of an era?. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1155-7	2.2	14
236	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 317-28	4.4	150
235	Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 385-94	4.4	28
234	The role of adjuvant anthracyclines for breast cancer treatment: Can we use molecular predictors?. 2009 , 1, 5-11		
233	Cyclophosphamide and cancer: golden anniversary. 2009 , 6, 638-47		457
232	Chemotherapy for early-stage breast cancer: a brief history. <i>British Journal of Cancer</i> , 2009 , 101 Suppl 1, S2-5	8.7	22

231	Breast cancer: beyond the cutting edge. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 2479-98	4	9
230	Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. 2009 , 27, 2230-9		11
229	Cloning and pharmacological characterization of a novel gene encoding human nucleoside transporter 1 (hNT1) from a human breast cancer cDNA library. 2009 , 84, 45-51		3
228	Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. 2009 , 11, 204		24
227	Adjuvant chemotherapy in older women with early-stage breast cancer. 2009 , 360, 2055-65		417
226	Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. 2009 , 27, 873-86		29
225	Predicting anthracycline benefit: have we made any progress?. 2009 , 21, 507-15		8
224	Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. 2010 , 11, 115-28		91
223	Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. 2010 , 17, 190-8		6
222	Breast Cancer OncoGuia. 2010 , 12, 113-38		7
221	Duration of chemotherapy for early stage breast cancer: have we reached the limit? What is the survival impact of amenorrhea?. 2010 , 11, 59-62		
220	Combined therapeutic effect of a monoclonal anti-idiotypic tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 379-89	4.4	25
219	Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 25-32	4.4	14
218	Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 303-10	4.4	22
217	CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 163-9	4.4	13
216	Changes to adjuvant systemic therapy in breast cancer: a decade in review. 2010 , 10, 196-208		20
215	Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse. 2010 , 10, 648		80
214	Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. 2010 , 13, 381-7		89

213	Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. <i>British Journal of Cancer</i> , 2010 , 102, 1003-9	8.7	125
212	Management of breast cancer in older adults. 89-109		
211	[Pharmaceutical therapy of breast cancer]. 2010 , 54, 237-54		3
210	Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II). 2010 , 1, 769-775		8
209	Eyelash preservation during chemotherapy and topical prostaglandin therapy. 2010 , 170, 1269-70		4
208	Aortic stiffness increases upon receipt of anthracycline chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 166-72	2.2	102
207	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (. 2010 , 21, 1974-1981		161
206	Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 77-82	2.2	115
205	Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer. 2010 , 21, 1228-1232		4
204	The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. 2010 , 5, 395-400		53
203	Chemotherapy for breast cancer (Review). 2010 , 24, 1121-31		82
202	Lifestyle and adiponectin level: four-year follow-up of controlled trials. 2010 , 170, 1270-1		4
201	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. 2010 , 21, 264-266		1
200	[Chemotherapy for early breast cancer: practices in 2010]. 2010 , 39, F79-84		2
199	The impact of young age on breast cancer outcome. 2010 ,		23
198	Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. 2010 , 7, 22-36		87
197	Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?. 2010 , 19, 649-68		11
196	Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. 2010 , 21, 2153-2160		57

195	Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. 2010 , 49, 1235-45		11
194	Breast cancer medications and vision: effects of treatments for early-stage disease. 2011 , 36, 867-85		51
193	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2011 , 22 Suppl 6, vi12-24		177
192	Challenges in the gynecologic care of premenopausal women with breast cancer. 2011 , 86, 229-40		13
191	Anthracyclines in the adjuvant treatment of breast cancer: state of the art. 2011 , 9, 5-10		
190	Breast cancer and fertility preservation. 2011 , 95, 1535-43		60
189	Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. 2011 , 18, 180-90		19
188	Basic cancer biology and immunology. 35-48		
187	Breast cancer and fertility preservation. 49-61		
186	Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer. 2011 , 14, 223-8		
185	Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. 2011 , 97, 280-285		3
184	Invasive breast cancer. 2011 , 9, 136-222		99
183	Use of non-anthracycline regimens in early stage breast cancer in Australia. 2011 , 7, 4-10		8
182	Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. 2011 , 13, 485-98		22
181	Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making. 2011 , 12, 286-301		9
180	Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4498-504	2.2	115
179	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 859-67	2.2	158
178	CMF revisited in the 21st century. 2012 , 23, 305-11		18

177	A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. 2012 , 23, 1121-1129		8
176	Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4071-6	2.2	69
175	Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer. 2012 , 7, 289-95		10
174	The impact of international guidelines on breast cancer management. 2012 , 1, 73-82		
173	TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 531-7	4.4	31
172	Outcome of special types of luminal breast cancer. 2012 , 23, 1428-36		79
171	Clinically-relevant anticancer-antidepressant drug interactions. 2012 , 8, 173-99		11
170	Triple negative breast cancer - our experience and review. 2012 , 3, 12-6		27
169	Achieving optimal dose intensity with adjuvant chemotherapy in elderly breast cancer patients: a 10-year retrospective study in a UK institution. 2012 , 18, 16-22		7
168	A population-based study on the implementation of treatment recommendations for chemotherapy in early breast cancer. 2012 , 12, 102-9		6
167	Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. 2012 , 83, 99-111		34
166	A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 863-72	4.4	30
165	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. 2013 , 14, 1121-1128		93
164	Extended adjuvant chemotherapy in endocrine non-responsive disease. <i>Breast</i> , 2013 , 22 Suppl 2, S161-43.6		4
163	Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels. 2013 , 92, 247-56		33
162	Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer. 2013 , 16, 729-39		29
161	Chemotherapy regimens in early breast cancer: major controversies and future outlook. 2013 , 13, 165-78		16
160	Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2013 , 10, 164-192		18

159	Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. 2013 , 73, 556-583		41
158	Adjuvant chemotherapy: which patient? What regimen?. 2013 , 3-8		3
157	HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer. 2014 , 29, e187-92		3
156	Chemotherapy in Breast Cancer. 2014 , 37, 75		2
155	Metronomic Chemotherapy. 2014 ,		2
154	Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2010-7	2.2	77
153	Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 143-52	4.4	40
152	Breast Cancer. 2014 ,		3
151	Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. 2014 , 74, 603-9		3
150	Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014 , 32, 2311-7	2.2	60
149	Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer. 2014 , 26, 692-6		7
148	Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. 2014 , 3, 198		28
147	Update on adjuvant chemotherapy for early breast cancer. 2014 , 8, 125-33		27
146	Breast carcinoma. 679-690		
145	Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. 2015 , 36, 5473-83		40
144	Adjuvant Chemotherapy in Breast Cancer. 2015 , 335-351		
143	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. 2015 , 15, e277-85		5
142	Patients' satisfaction in early breast cancer treatment: Change in treatment over time and impact of HER2-targeted therapy. 2015 , 94, 270-8		4

141	Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland. <i>Breast Cancer Research and Treatment</i> , 2015 , 153, 573-82	4.4	21
140	Progress in adjuvant chemotherapy for breast cancer: an overview. 2015 , 13, 195		167
139	The Globalization of Cooperative Groups. 2015 , 42, 693-712		5
138	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. 2015 , 51, 2314-20		33
137	Long-term cost-effectiveness of Oncotype DX [®] versus current clinical practice from a Dutch cost perspective. 2015 , 4, 433-45		16
136	Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. <i>Journal of Clinical Oncology</i> , 2015 , 33, 65-73	2.2	103
135	Breast Diseases. 2015 ,		2
134	The Impact of Chemotherapy on Complications Associated with Mastectomy and Immediate Autologous Tissue Reconstruction. 2016 , 82, 713-717		5
133	Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. 2016 , 23, e576-e582		10
132	Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes. 2016 , 23, 3145-52		5
131	The relationship between nuclear factor (NF)- B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. 2016 , 6, 31804		35
130	Adjuvant treatment for older women with invasive breast cancer. 2016 , 12, 129-45; quiz 145-6		9
129	Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. <i>Breast</i> , 2016 , 27, 69-77	3.6	7
128	Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. 2016 , 139, 12-22		30
127	Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. 2016 , 91, 274-282		8
126	Quality evaluation of medical care for breast cancer in Japan. 2016 , 28, 110-3		6
125	Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment. 2016 , 36, 375-90		5
124	Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy. 2016 , 108,		15

123	An overview of triple-negative breast cancer. 2016 , 293, 247-69	268
122	Liver resection for HER2-enriched breast cancer metastasis: case report and review of the literature. 2017 , 3, 33	0
121	Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. 2017 , 12, 152-158	9
120	The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer. 2017 , 9, 210-216	
119	Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings. 2017 , 569-576	
118	Pharmacogenetics: Focus on Breast Cancer Treatment. 2017 , 02,	
117	A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Doxorubicin Concentrations in Human Plasma. 2017 , 14,	1
116	Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index. 2017 , 11, 2227-2237	6
115	Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis. 2017 , 20, 347-355	8
114	Breast Cancer, Including Brief Discussion of Male Breast Cancer. 2018 , 375-396	
113	Therapeutic Strategies for Breast Cancer. 2018 , 315-330.e7	3
112	Adjuvant and Neoadjuvant Systemic Therapies for Early-Stage Breast Cancer. 2018 , 752-762.e4	
111	Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer. 2018 , 885-906.e8	1
110	Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 rs4880, CYP2C19 rs4244285, and FCGR2A rs1801274 Polymorphisms in a Breast Cancer Population in Iraqi Women. 2018 , 18, e863-e868	7
109	Combination of Trastuzumab and Radiotherapy in the Adjuvant Treatment of Breast Cancer: A Single Center Experience and Focus on the Cardiac Safety. 2018 , 09,	
108	Antiproliferative activity of the combination of doxorubicin/quercetin on MCF7 breast cancer cell line: A combined study using colorimetric assay and synchrotron infrared microspectroscopy. 2018 , 95, 141-147	8
107	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). 2018 , 102, 40-48	6
106	Timing and Delays in Breast Cancer Evaluation and Treatment. 2018 , 25, 2829-2838	63

105	Spotlight on the utility of the Oncotype DX breast cancer assay. 2018 , 10, 89-100		32
104	Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review. 2018 , 19, 30		39
103	The Evolving Role of Postmastectomy Radiation Therapy. 2018 , 98, 801-817		1
102	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2338-2348	2.2	25
101	The use of a predictive statistical model to make a virtual control arm for a clinical trial. 2019 , 14, e0221336		5
100	De-escalation yes, but not at the expense of efficacy: in defense of better treatment. <i>Npj Breast Cancer</i> , 2019 , 5, 25	7.8	2
99	Breast Cancer Treatment: A Review. 2019 , 321, 288-300		1202
98	Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. 2019 , 46, 83-99		10
97	Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. 2019 , 25, 237-242		1
96	Drug Combinations in Breast Cancer Therapy. 2019 , 7, 3-23		84
95	Response to neoadjuvant chemotherapy in breast cancer in a resource limited environment. 2019 , 7, 82		
94	Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. 2019 , 21, 153		7
93	Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines. 2019 , 25, 62-68		4
92	Adjuvant Chemotherapy for HER2-Negative Early-Stage Breast Cancer. 2019 , 357-381		
91	Optimizing multi-modal cancer treatment under 3D spatio-temporal tumor growth. 2019 , 307, 53-69		6
90	Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study. 2020 , 44, 100556		1
89	Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon. <i>Breast</i> , 2020 , 50, 39-48	3.6	6
88	Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis. 2021 , 21, e22-e37		0

87	A Pharmacocybernetics Approach to Designing an Oncology Drug Interaction Database for Clinical Practice. 2021 , 169-227		
86	Multi-Targeted Anticancer Activity of Imidazolate Phosphane Gold(I) Compounds by Inhibition of DHFR and TrxR in Breast Cancer Cells. 2020 , 8, 602845		4
85	Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. 2021 , 9,		6
84	Fertility and Breast Cancer. 2021 , 13, 72-80		
83	Interstitial lung disease associated with adjuvant and neoadjuvant chemotherapy in early breast cancer. 2021 , 19, 169		3
82	A Retrospective Analysis of Metronomic Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) Versus Docetaxel and Cyclophosphamide (TC) as Adjuvant Treatment in Early Stage, Hormone Receptor Positive, HER2 Negative Breast Cancer. 2021 ,		0
81	Chemotherapy for Breast Cancer. 2001 , 309-341		0
80	Benign and Malignant Diseases of the Breast. 2008 , 2005-2035		1
79	Advances in adjuvant chemotherapy of early stage breast cancer. <i>Cancer Treatment and Research</i> , 2008 , 141, 37-53	3.5	3
78	Adjuvant chemotherapy. <i>Cancer Treatment and Research</i> , 2009 , 151, 121-37	3.5	2
77	Outcome of African American Women with Breast Cancer in Cooperative Group Clinical Trials. 2006 , 267-295		1
76	Postmastectomy radiotherapy. <i>Cancer Treatment and Research</i> , 2000 , 103, 39-55	3.5	3
75	Role of Modeling in Pharmacotherapeutics. 2006 , 3-27		1
74	Mammakarzinom. 1119-1183		1
73	Putting the taxanes to work: unanswered questions. 1998 , 152, 305-13		1
72	Benign and Malignant Diseases of the Breast. 2001 , 1699-1732		2
71	The role of anthracyclines in adjuvant chemotherapy of breast cancer: a critical appraisal. 1996 , 140, 191-9		1
70	Summary. 1996 , 325-335		7

69	Adjuvant Therapy of Breast Cancer. 1994 , 8, 213-231		7
68	Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients. 2012 , 23, 991-5		7
67	Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. <i>Oncologist</i> , 1998 , 3, 300-313	5.7	11
66	Concordance assessment of Watson for Oncology in breast cancer chemotherapy: first China experience.. 2019 , 8, 389-401		4
65	Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends. 2019 , 19, 691-712		14
64	Chemotherapy. 2004 , 327-370		0
63	STUDY OF ACUTE VIRAL MENINGOENCEPHALITIS IN CHILDREN IN SUB-HIMALAYAN TARAI REGION: CLINICO-EPIDEMIOLOGICAL, ETIOLOGICAL, AND IMAGING PROFILE. 2015 , 02, 177-181		4
62	A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019. 2020 , 9,		2
61	Potentiation of Low-Dose Doxorubicin Cytotoxicity by Affecting P-Glycoprotein through Caryophyllane Sesquiterpenes in HepG2 Cells: an in Vitro and in Silico Study. 2020 , 21,		14
60	Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. 2007 , 14, 227-33		9
59	Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. 2007 , 22, 237-43		33
58	Toxicity and Tolerability Study of Adjuvant TAC Regimen Chemotherapy in Korean Patients with Breast Cancer. 2011 , 14, S44		6
57	Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy: Are We There Yet?. 2012 , 03, 90-102		1
56	Protective effect of astragalus polysaccharides on liver injury induced by several different chemotherapeutics in mice. 2014 , 15, 10413-20		27
55	Types of Cancers Prevailing in Pakistan and their Management Evaluation. 2015 , 16, 3605-16		3
54	A careful reassessment of anthracycline use in curable breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 134	7.8	6
53	Breast Cancer Epidemiology, Treatment, and Prevention. 2000 , 871-883		1
52	Chemotherapy as an Adjunct to Surgery. 2001 , 1659-1676		

- 51 Breast Cancer. **2001**, 109-129
- 50 Adjuvante systemische Therapie. **2002**, 227-253
- 49 Early Breast Cancer. **2003**, 331-342
- 48 Breast cancer. *Cancer Chemotherapy and Biological Response Modifiers*, **2003**, 21, 585-608
- 47 Neoplastic Diseases. **2004**, 479-504
- 46 Adjuvante systemische Therapie. **2006**, 277-296
- 45 Adjuvant Therapy of Breast Cancer. **2006**, 153-219
- 44 Mammaerkrankungen. **2008**, 325-397
- 43 A STUDY OF TOLERABILITY OF DOCETAXEL WITH CYCLOPHOSPHAMIDE (TC) THERAPY AS A POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR BREAST CANCER. *Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)*, **2008**, 69, 2747-2751 ○
- 42 Early Symptomatic Breast Cancer. **2009**, 1-67
- 41 Chemotherapeutic Agents. **2010**, 353-372
- 40 Adjuvant Systemic Therapy. **2010**, 741-753
- 39 Entwicklung der Chemotherapie in der Gynäkologie. **2011**, 499-512
- 38 Brusttumoren. **2011**, 475-486
- 37 Interaction of Chemotherapy, Radiotherapy, and Timing. **2013**, 59-70
- 36 Adjuvant chemotherapy and biological therapies for early-stage breast cancer. **2013**, 478-488
- 35 Systemic Therapy. **2014**, 381-420
- 34 Overview of Metronomic Chemotherapy in SWOG Breast Cancer Cooperative Group Clinical Trials. **2014**, 111-118

33	Unanswered questions in the adjuvant therapy of breast cancer. <i>Cancer Treatment and Research</i> , 1992 , 60, 257-78	3.5	
32	ADJUVANT THERAPY IN BREAST CANCER. <i>Obstetrics and Gynecology Clinics of North America</i> , 1994 , 21, 693-707	3.3	1
31	Adjuvant Drug Treatment for Resectable Breast Cancer. <i>Oncologist</i> , 1997 , 2, 351-358	5.7	1
30	Early Breast Cancer. 1999 , 511-532		1
29	Adjuvant/Neoadjuvant Systemic Therapies in Breast Cancer. 2015 , 329-338		
28	Mammakarzinom. 2015 , 1-15		
27	Adjuvant Systemic Treatment for Breast Cancer: An Overview. 2016 , 311-321		
26	Systemic Therapy. 2016 , 335-390		
25	Principes des chimiothérapies adjuvantes et néoadjuvantes des cancers du sein localisés. 2016 , 79-87		
24	Adjuvant Systemic Chemotherapy for HER2-Negative Disease. 2016 , 131-187		
23	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017 , 1-34	0.3	
22	Breast Cancer. 2017 ,		
21	Pharmacogenetics as Personalized Medicine: Association Investigation of SOD2 Rs4880, CYP2C19 Rs4244285 and FCGR2A Rs1801274 Polymorphisms with Breast Cancer Population in Iraqi Women. <i>Journal of Cancer Prevention & Current Research</i> , 2017 , 8,	1.3	
20	Adjuvant Systemic Chemotherapy for HER2-Negative Disease. 2019 , 129-171		
19	Evaluation of Doxycycline and Cyclophosphamide in Combination with Adjuvant Treatment in Early Breast Cancer Females: Role of Certain Biomarkers. <i>Asian Journal of Biological Sciences</i> , 2020 , 13, 181-188	0.3	
18	Traitement adjuvant du cancer du sein n'exprimant pas HER2. 2007 , 167-187		
17	Early Breast Cancer (Stage I and Stage II): Tailored Systemic Therapy for Endocrine-Resistant Breast Cancer. 2006 , 308-326		
16	Less Toxic Chemotherapy in Locally Advanced Breast Cancer. <i>Southern Medical Journal</i> , 2020 , 113, 559-563		1

15	How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?. <i>Gland Surgery</i> , 2012 , 1, 156-8	2.2	
14	Complicaciones neutropénicas debidas a tratamiento citostático en pacientes con cáncer de mama tratadas con quimioterapia adyuvante. Estudio retrospectivo. 2000 , 2, 253-258		
13	Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.. <i>Case Reports in Oncological Medicine</i> , 2022 , 2022, 2709062	0.9	1
12	Pneumocystis jirovecii Pneumonia in Three Patients With Breast Cancer Receiving Neoadjuvant Dose-Dense Chemotherapy.. <i>Cureus</i> , 2022 , 14, e21812	1.2	0
11	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).. <i>Breast Cancer Research and Treatment</i> , 2022 , 193, 555	4.4	1
10	Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer.. <i>Cost Effectiveness and Resource Allocation</i> , 2022 , 20, 9	2.4	0
9	Table_1.doc. 2021 ,		
8	Breast Cancer. 2022 , 151-192		
7	Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions. <i>Drug Safety</i> ,	5.1	0
6	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. <i>British Journal of Cancer</i> ,	8.7	0
5	The landscape of systemic therapy for early stage triple negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> ,	4	1
4	Anthracyclines in the treatment of early breast cancer friend or foe?. <i>Breast</i> , 2022 , 65, 67-76	3.6	0
3	Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC).		0
2	Neoplasms of the Breast. 1-62		0
1	Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.		0